An antilipolytic agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Acipimox

Item No. 26090

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-methyl-2-pyrazinecarboxylic acid, 4-oxide
CAS Number
51037-30-0
Molecular Formula
C6H6N2O3
Formula Weight
154.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: slightly solublePBS (pH 7.2): 5 mg/ml
λmax
233, 276 nm
SMILES
CC1=CN=C(C(O)=O)C=[N+]1[O-]
InChi Code
InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)
InChi Key
DJQOOSBJCLSSEY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 mg

    $49

    Add

    1 g

    $86

    Add

    5 g

    $259

    Add

    10 g

    $376

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Acipimox is an antilipolytic agent.1 It inhibits lipolysis induced by noradrenaline and theophylline in rat epididymal adipocytes when used at a concentration of 1 μM. Acipimox (3 and 12 mg/kg, p.o.) decreases plasma free fatty acid levels in rats. It reduces plasma fatty acid concentration, the number of atherosclerotic plaques, and matrixmetalloproteinase-2 (MMP-2) activity in ApoE-/- mice fed a palmitate-rich diet.2 Acipimox also reduces fasting blood glucose and plasma insulin levels as well as plasma free fatty acid and triglyceride levels in a rat model of diabetes induced by streptozotocin (Item No. 13104).3 Formulations containing acipimox have been used in the treatment of hyperlipidemia in patients with non-insulin-dependent diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lovisolo, P.P., Briatico-Vangosa, G., Orsini, G., et al. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action. Pharmacol. Res. Commun. 13(2), 151-161 (1981).

    2. Feipeng, J., Jiang, S., Yang, D., et al. Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet. Biochem. Bioph. Res. Commun. 428(1), 86-92 (2012).

    3. Kim, Y.W., Kim, J.Y., and Lee, S.K. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats. J. Korean Med. Sci. 10(1), 24-30 (1995).